{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:21:50Z","timestamp":1794475310642,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04288-5","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:25:12Z","timestamp":1772839512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Macrophage-centered immunotherapy for osteosarcoma: mechanisms, repolarization, and translational strategies"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liandi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wending","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"4288_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/sicotj\/2017028","volume":"4","author":"A Misaghi","year":"2018","unstructured":"Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12.","journal-title":"SICOT J"},{"key":"4288_CR2","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/j.jbo.2024.100607","volume":"46","author":"J Yang","year":"2024","unstructured":"Yang J, Lou S, Yao T. Trends in primary malignant bone cancer incidence and mortality in the United States, 2000\u20132017: A population-based study. J Bone Oncol. 2024;46:100607.","journal-title":"J Bone Oncol"},{"key":"4288_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23:192.","journal-title":"Mol Cancer"},{"key":"4288_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cvsm.2023.12.007","volume":"54","author":"JN Bryan","year":"2024","unstructured":"Bryan JN. Updates in Osteosarcoma. Vet Clin North Am Small Anim Pract. 2024;54:523\u201339.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"4288_CR5","doi-asserted-by":"publisher","first-page":"1579822","DOI":"10.3389\/fimmu.2025.1579822","volume":"16","author":"Z Han","year":"2025","unstructured":"Han Z, Chen G, Wang D. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies. Front Immunol. 2025;16:1579822.","journal-title":"Front Immunol"},{"key":"4288_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"key":"4288_CR7","doi-asserted-by":"publisher","unstructured":"Yu T, Jiang W, Wang Y, Zhou Y, Jiao J, Wu M. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review). Int J Oncol. 2024;64(4):40. https:\/\/doi.org\/10.3892\/ijo.2024.5628.","DOI":"10.3892\/ijo.2024.5628"},{"key":"4288_CR8","doi-asserted-by":"publisher","first-page":"100635","DOI":"10.1016\/j.jbo.2024.100635","volume":"48","author":"A Barzegari","year":"2024","unstructured":"Barzegari A, Salemi F, Kamyab A, Aratikatla A, Nejati N, Valizade M, Eltouny E, Ebrahimi A. The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence. J Bone Oncol. 2024;48:100635.","journal-title":"J Bone Oncol"},{"key":"4288_CR9","doi-asserted-by":"publisher","first-page":"586580","DOI":"10.3389\/fonc.2020.586580","volume":"10","author":"ZW Luo","year":"2020","unstructured":"Luo ZW, Liu PP, Wang ZX, Chen CY, Xie H. Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy. Front Oncol. 2020;10:586580.","journal-title":"Front Oncol"},{"key":"4288_CR10","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.3390\/ijms21155207","volume":"21","author":"F Cersosimo","year":"2020","unstructured":"Cersosimo F, Lonardi S, Bernardini G, Telfer B, Mandelli GE, Santucci A, Vermi W, Giurisato E. Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. Int J Mol Sci. 2020;21:5207.","journal-title":"Int J Mol Sci"},{"key":"4288_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44:145.","journal-title":"J Exp Clin Cancer Res"},{"key":"4288_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang R, Kang T, Chen S. The role of tumor-associated macrophages in tumor immune evasion. J Cancer Res Clin Oncol. 2024;150:238.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4288_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bleriot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20:983\u201392.","journal-title":"Cell Mol Immunol"},{"key":"4288_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"4288_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.","journal-title":"F1000Prime Rep"},{"key":"4288_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.","journal-title":"Signal Transduct Target Ther"},{"key":"4288_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1042\/CS20220531","volume":"137","author":"Z Strizova","year":"2023","unstructured":"Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley Lily K, Striz I. M1\/M2 macrophages and their overlaps \u2013 myth or reality? Clin Sci. 2023;137:1067\u201393.","journal-title":"Clin Sci"},{"key":"4288_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11033-023-09014-y","volume":"51","author":"E Apeku","year":"2024","unstructured":"Apeku E, Tantuoyir MM, Zheng R, Tanye N. Exploring the polarization of M1 and M2 macrophages in the context of skin diseases. Mol Biol Rep. 2024;51:269.","journal-title":"Mol Biol Rep"},{"key":"4288_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.","journal-title":"BMC Cancer"},{"key":"4288_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1159\/000364945","volume":"6","author":"CD Mills","year":"2014","unstructured":"Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun. 2014;6:716\u201326.","journal-title":"J Innate Immun"},{"key":"4288_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12951-025-03292-3","volume":"23","author":"S Yang","year":"2025","unstructured":"Yang S, Fan L, Yin L, Zhao Y, Li W, Zhao R, Jia X, Dong F, Zheng Z, Zhao D, Wang J. Ginseng exosomes modulate M1\/M2 polarisation by activating autophagy and target IKK\/Ismall ka, CyrillicB\/NF-small ka, CyrillicB to alleviate inflammatory bowel disease. J Nanobiotechnol. 2025;23:198.","journal-title":"J Nanobiotechnol"},{"key":"4288_CR22","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1039\/D5BM00848D","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang J, Gao W, Ma G. IL12-based phototherapeutic nanoparticles through remodeling tumor-associated macrophages combined with immunogenic tumor cell death for synergistic cancer immunotherapy. Biomater Sci. 2025;13:5730\u201340.","journal-title":"Biomater Sci"},{"key":"4288_CR23","doi-asserted-by":"publisher","first-page":"1584450","DOI":"10.3389\/fimmu.2025.1584450","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Jiang S, Lv J, Feng W, Yu Y, Zhao H. Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights. Front Immunol. 2025;16:1584450.","journal-title":"Front Immunol"},{"key":"4288_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41420-025-02626-2","volume":"11","author":"X Lu","year":"2025","unstructured":"Lu X, Zhang X, Zhang F, Wang W, Liu R, Hou Y, Shi W, Li J, Peng C. SPON2 facilitates osteosarcoma development by inducing M2 macrophage polarization through activation of the NF-kappaB\/VEGF signaling axis. Cell Death Discov. 2025;11:352.","journal-title":"Cell Death Discov"},{"key":"4288_CR25","doi-asserted-by":"publisher","first-page":"e2409870","DOI":"10.1002\/advs.202409870","volume":"12","author":"W Liu","year":"2025","unstructured":"Liu W, Li L, Bai X, Zhang M, Lv W, Ma Y, Sun Y, Zhang H, Jiang Q, Yao Q, Zhang ZY. Osteosarcoma Cell-Derived Migrasomes Promote Macrophage M2 Polarization to Aggravate Osteosarcoma Proliferation and Metastasis. Adv Sci (Weinh). 2025;12:e2409870.","journal-title":"Adv Sci (Weinh)"},{"key":"4288_CR26","doi-asserted-by":"publisher","unstructured":"Mishra AK, Banday S, Bharadwaj R, et al. Macrophages as a potential immunotherapeutic target in solid cancers. Vaccines (Basel). 2022;11(1):55. https:\/\/doi.org\/10.3390\/vaccines11010055.","DOI":"10.3390\/vaccines11010055"},{"key":"4288_CR27","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/cancers16162801","volume":"16","author":"R Tatsuno","year":"2024","unstructured":"Tatsuno R, Komohara Y, Pan C, Kawasaki T, Enomoto A, Jubashi T, Kono H, Wako M, Ashizawa T, Haro H, Ichikawa J. Surface Markers and Chemokines\/Cytokines of Tumor-Associated Macrophages in Osteosarcoma and Other Carcinoma Microenviornments-Contradictions and Comparisons. Cancers (Basel). 2024;16:2801.","journal-title":"Cancers (Basel)"},{"key":"4288_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2018.10.011","volume":"440\u2013441","author":"Y Han","year":"2019","unstructured":"Han Y, Guo W, Ren T, Huang Y, Wang S, Liu K, Zheng B, Yang K, Zhang H, Liang X. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2\/STAT3 axis. Cancer Lett. 2019;440\u2013441:116\u201325.","journal-title":"Cancer Lett"},{"key":"4288_CR29","doi-asserted-by":"publisher","first-page":"1394284","DOI":"10.3389\/fimmu.2024.1394284","volume":"15","author":"S Orrapin","year":"2024","unstructured":"Orrapin S, Moonmuang S, Udomruk S, Yongpitakwattana P, Pruksakorn D, Chaiyawat P. Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms. Front Immunol. 2024;15:1394284.","journal-title":"Front Immunol"},{"key":"4288_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41698-023-00431-7","volume":"7","author":"F Tang","year":"2023","unstructured":"Tang F, Wang Y, Zeng Y, Xiao A, Tong A, Xu J. Tumor-associated macrophage-related strategies for glioma immunotherapy. NPJ Precis Oncol. 2023;7:78.","journal-title":"NPJ Precis Oncol"},{"key":"4288_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31.","journal-title":"NPJ Precis Oncol"},{"key":"4288_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12964-024-01492-2","volume":"22","author":"MA Caricasulo","year":"2024","unstructured":"Caricasulo MA, Zanetti A, Terao M, Garattini E, Paroni G. Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer. Cell Commun Signal. 2024;22:127.","journal-title":"Cell Commun Signal"},{"key":"4288_CR33","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Hern\u00e1ndez AA, Vel\u00e1zquez-Enr\u00edquez JM, Santos-\u00c1lvarez JC, et al. The role of extracellular vesicles in idiopathic pulmonary fibrosis progression: an approach on their therapeutics potential. Cells. 2022;11(4):630. https:\/\/doi.org\/10.3390\/cells11040630.","DOI":"10.3390\/cells11040630"},{"key":"4288_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12079-022-00673-3","volume":"16","author":"C Zeltz","year":"2022","unstructured":"Zeltz C, Navab R, Heljasvaara R, Kusche-Gullberg M, Lu N, Tsao MS, Gullberg D. Integrin alpha11beta1 in tumor fibrosis: more than just another cancer-associated fibroblast biomarker? J Cell Commun Signal. 2022;16:649\u201360.","journal-title":"J Cell Commun Signal"},{"key":"4288_CR35","doi-asserted-by":"publisher","first-page":"1157537","DOI":"10.3389\/fimmu.2023.1157537","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Du J, Shen X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. Front Immunol. 2023;14:1157537.","journal-title":"Front Immunol"},{"key":"4288_CR36","doi-asserted-by":"publisher","unstructured":"Teo KYW, Zhang S, Loh JT, et al. Mesenchymal stromal cell exosomes mediate M2-like macrophage polarization through CD73\/Ecto-5'-Nucleotidase activity. Pharmaceutics. 2023;15(5):1489. https:\/\/doi.org\/10.3390\/pharmaceutics15051489.","DOI":"10.3390\/pharmaceutics15051489"},{"key":"4288_CR37","doi-asserted-by":"publisher","first-page":"e15276","DOI":"10.1002\/advs.202415276","volume":"12","author":"Z Huang","year":"2025","unstructured":"Huang Z, Zhu J, Hu J, Wang X, Ma X, Xu E, Zhu K, Zhang C. Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1\u2009+\u2009Macrophage Production to Enhance Antitumor Immunity. Adv Sci (Weinh). 2025;12:e15276.","journal-title":"Adv Sci (Weinh)"},{"key":"4288_CR38","doi-asserted-by":"publisher","first-page":"115293","DOI":"10.1016\/j.intimp.2025.115293","volume":"163","author":"X Li","year":"2025","unstructured":"Li X, Guo X, Wang W, Liu P. Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression. Int Immunopharmacol. 2025;163:115293.","journal-title":"Int Immunopharmacol"},{"key":"4288_CR39","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.medidd.2022.100136","volume":"15","author":"S Ravichandran","year":"2022","unstructured":"Ravichandran S, Manickam N, Kandasamy M. Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19. Med Drug Discov. 2022;15:100136.","journal-title":"Med Drug Discov"},{"key":"4288_CR40","doi-asserted-by":"publisher","unstructured":"Sato T, Sugiyama D, Koseki J, et al. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages. JCI Insight. 2025;10(1):e178146. https:\/\/doi.org\/10.1172\/jci.insight.178146.","DOI":"10.1172\/jci.insight.178146"},{"key":"4288_CR41","doi-asserted-by":"publisher","first-page":"27446","DOI":"10.1038\/s41598-025-13153-6","volume":"15","author":"J Kang","year":"2025","unstructured":"Kang J, Zhan J, Yuan Y, Wei Y, Xiao T, Li L, Fang H, Tian A. CSF1R inhibitor (PLX3397) alleviates experimental periodontitis by reducing macrophage senescence through the PI3K\/AKT\/FOXO1 signaling pathway. Sci Rep. 2025;15:27446.","journal-title":"Sci Rep"},{"key":"4288_CR42","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL. CD47-SIRPalpha-targeted therapeutics: status and prospects. Immunooncol Technol. 2022;13:100070.","journal-title":"Immunooncol Technol"},{"key":"4288_CR43","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.3390\/cancers14143366","volume":"14","author":"LM Behrens","year":"2022","unstructured":"Behrens LM, van den Berg TK, van Egmond M. Targeting the CD47-SIRPalpha Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. Cancers (Basel). 2022;14:3366.","journal-title":"Cancers (Basel)"},{"key":"4288_CR44","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.3390\/cancers13246229","volume":"13","author":"N Dizman","year":"2021","unstructured":"Dizman N, Buchbinder EI. Cancer Therapy Targeting CD47\/SIRPalpha. Cancers (Basel). 2021;13:6229.","journal-title":"Cancers (Basel)"},{"key":"4288_CR45","doi-asserted-by":"publisher","first-page":"101099","DOI":"10.1016\/j.jpha.2024.101099","volume":"15","author":"Z Che","year":"2025","unstructured":"Che Z, Wang W, Zhang L, Lin Z. Therapeutic strategies targeting CD47-SIRPalpha signaling pathway in gastrointestinal cancers treatment. J Pharm Anal. 2025;15:101099.","journal-title":"J Pharm Anal"},{"key":"4288_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","volume":"10","author":"T Qu","year":"2022","unstructured":"Qu T, Li B, Wang Y. Targeting CD47\/SIRPalpha as a therapeutic strategy, where we are and where we are headed. Biomark Res. 2022;10:20.","journal-title":"Biomark Res"},{"key":"4288_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Peran M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17:44.","journal-title":"J Hematol Oncol"},{"key":"4288_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2326-6066.CIR-16-0259","volume":"5","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Xian M, Xiang S, Xiang D, Shao X, Wang J, Cao J, Yang X, Yang B, Ying M, He Q. All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages. Cancer Immunol Res. 2017;5:547\u201359.","journal-title":"Cancer Immunol Res"},{"key":"4288_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-9966-33-27","volume":"33","author":"JH Pahl","year":"2014","unstructured":"Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma. J Exp Clin Cancer Res. 2014;33:27.","journal-title":"J Exp Clin Cancer Res"},{"key":"4288_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.2011.543129","volume":"12","author":"K Ando","year":"2011","unstructured":"Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12:285\u201392.","journal-title":"Expert Opin Pharmacother"},{"key":"4288_CR51","doi-asserted-by":"publisher","first-page":"20706","DOI":"10.18632\/oncotarget.14982","volume":"8","author":"CF Chiang","year":"2017","unstructured":"Chiang CF, Chao TT, Su YF, Hsu CC, Chien CY, Chiu KC, Shiah SG, Lee CH, Liu SY, Shieh YS. Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-kappaB signaling. Oncotarget. 2017;8:20706\u201318.","journal-title":"Oncotarget"},{"key":"4288_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2020.00262","volume":"11","author":"C Pan","year":"2020","unstructured":"Pan C, Fujiwara Y, Horlad H, Shiraishi D, Iriki T, Tsuboki J, Ikeda T, Komohara Y. Flavonoid Compounds Contained in Epimedii Herba Inhibit Tumor Progression by Suppressing STAT3 Activation in the Tumor Microenvironment. Front Pharmacol. 2020;11:262.","journal-title":"Front Pharmacol"},{"key":"4288_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, Tian Y, Niu X, Wang Y, Torabian P, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16.","journal-title":"J Hematol Oncol"},{"key":"4288_CR54","doi-asserted-by":"publisher","unstructured":"B\u00e1ez DF. Graphene-based nanomaterials for photothermal therapy in cancer treatment. Pharmaceutics. 2023;15(9):2286. https:\/\/doi.org\/10.3390\/pharmaceutics15092286.","DOI":"10.3390\/pharmaceutics15092286"},{"key":"4288_CR55","doi-asserted-by":"publisher","first-page":"eadq7307","DOI":"10.1126\/sciadv.adq7307","volume":"11","author":"A Zotta","year":"2025","unstructured":"Zotta A, Toller-Kawahisa J, Palsson-McDermott EM, O\u2019Carroll SM, Henry OC, Day EA, McGettrick AF, Ward RW, Ryan DG, Watson MA, et al. Mitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion. Sci Adv. 2025;11:eadq7307.","journal-title":"Sci Adv"},{"key":"4288_CR56","doi-asserted-by":"publisher","first-page":"E2801","DOI":"10.1073\/pnas.1707929115","volume":"115","author":"E Giurisato","year":"2018","unstructured":"Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, et al. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. Proc Natl Acad Sci U S A. 2018;115:E2801\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4288_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/2767-9764.CRC-22-0243","volume":"3","author":"K Fukasawa","year":"2023","unstructured":"Fukasawa K, Lyu J, Kubo T, Tanaka Y, Suzuki A, Horie T, Tomizawa A, Osumi R, Iwahashi S, Tokumura K, et al. MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells. Cancer Res Commun. 2023;3:148\u201359.","journal-title":"Cancer Res Commun"},{"key":"4288_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00262-024-03759-6","volume":"73","author":"K Chupradit","year":"2024","unstructured":"Chupradit K, Muneekaew S, Wattanapanitch M. Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers. Cancer Immunol Immunother. 2024;73:170.","journal-title":"Cancer Immunol Immunother"},{"key":"4288_CR59","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382.","journal-title":"Nat Med"},{"key":"4288_CR60","doi-asserted-by":"publisher","unstructured":"Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial. J Immunother Cancer. 2020;8(2):e001561. https:\/\/doi.org\/10.1136\/jitc-2020-001561.","DOI":"10.1136\/jitc-2020-001561"},{"key":"4288_CR61","doi-asserted-by":"publisher","unstructured":"Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020;8(1):e000798. https:\/\/doi.org\/10.1136\/jitc-2020-000798.","DOI":"10.1136\/jitc-2020-000798"},{"key":"4288_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","volume":"14","author":"R Ran","year":"2025","unstructured":"Ran R, Chen X, Yang J, Xu B. Immunotherapy in breast cancer: current landscape and emerging trends. Exp Hematol Oncol. 2025;14:77.","journal-title":"Exp Hematol Oncol"},{"key":"4288_CR63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-024-02050-7","volume":"23","author":"Y Fu","year":"2024","unstructured":"Fu Y, Tao J, Liu T, Liu Y, Qiu J, Su D, Wang R, Luo W, Cao Z, Weng G, et al. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Mol Cancer. 2024;23:140.","journal-title":"Mol Cancer"},{"key":"4288_CR64","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.csbj.2025.05.038","volume":"27","author":"A Lomas Redondo","year":"2025","unstructured":"Lomas Redondo A, Sanchez Velazquez JM, Garcia Tejedor AJ, Sanchez-Arevalo Lobo VJ. Deep learning based deconvolution methods: A systematic review. Comput Struct Biotechnol J. 2025;27:2544\u201365.","journal-title":"Comput Struct Biotechnol J"},{"key":"4288_CR65","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, Bu T, Xiao Q, Ding K. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10:268.","journal-title":"Signal Transduct Target Ther"},{"key":"4288_CR66","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.32604\/or.2025.064677","volume":"33","author":"Y Mayasin","year":"2025","unstructured":"Mayasin Y, Osinnikova M, Osadchaya D, Dmitrienko V, Gorodilova A, Kharisova C, Kitaeva K, Filin I, Solovyeva V, Rizvanov A. Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy. Oncol Res. 2025;33:2221\u201342.","journal-title":"Oncol Res"},{"key":"4288_CR67","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X Chu","year":"2024","unstructured":"Chu X, Tian Y, Lv C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol Cancer. 2024;23:150.","journal-title":"Mol Cancer"},{"key":"4288_CR68","doi-asserted-by":"publisher","first-page":"1558091","DOI":"10.3389\/fimmu.2025.1558091","volume":"16","author":"Y He","year":"2025","unstructured":"He Y, Hong Q, Chen S, Zhou J, Qiu S. Reprogramming tumor-associated macrophages in gastric cancer: a pathway to enhanced immunotherapy. Front Immunol. 2025;16:1558091.","journal-title":"Front Immunol"},{"key":"4288_CR69","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-019-0730-9","volume":"12","author":"D Wang","year":"2019","unstructured":"Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1\/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019;12:42.","journal-title":"J Hematol Oncol"},{"key":"4288_CR70","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"4288_CR71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"4288_CR72","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, Cheng G, Zhang P, Chen W, Chen Y, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18:62.","journal-title":"J Hematol Oncol"},{"key":"4288_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther. 2024;9:68.","journal-title":"Signal Transduct Target Ther"},{"key":"4288_CR74","doi-asserted-by":"publisher","first-page":"642285","DOI":"10.3389\/fimmu.2021.642285","volume":"12","author":"TD Ricketts","year":"2021","unstructured":"Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Front Immunol. 2021;12:642285.","journal-title":"Front Immunol"},{"key":"4288_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7:331.","journal-title":"Signal Transduct Target Ther"},{"key":"4288_CR76","doi-asserted-by":"publisher","unstructured":"Roznovan CN, M\u0103ru\u021bescu LG, Gradisteanu Pircalabioru G. Immuno-oncology at the crossroads: confronting challenges in the quest for effective cancer therapies. Int J Mol Sci. 2025;26(13):6177. https:\/\/doi.org\/10.3390\/ijms26136177.","DOI":"10.3390\/ijms26136177"},{"key":"4288_CR77","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib14010016","volume":"14","author":"H In","year":"2025","unstructured":"In H, Park M, Lee H, Han KH. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies (Basel). 2025;14:16.","journal-title":"Antibodies (Basel)"},{"key":"4288_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N Yin","year":"2024","unstructured":"Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Ther. 2024;9:126.","journal-title":"Signal Transduct Target Ther"},{"key":"4288_CR79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11:103.","journal-title":"Biomark Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04288-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04288-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04288-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:21:59Z","timestamp":1776176519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04288-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4288"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04288-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}